Medinotec Inc. reported first-quarter 2027 results with revenue of $2.65M and net income of $222014 driven by higher distribution volumes and initial U.S. commercialization following recent regulatory clearances.
Financial Highlights
- Revenue: $2.65M for Q1 2027 (three months ended May 31, 2026), compared with $2.13M in the year-ago quarter; YoY change 24%.
- Net income: $222,014 for Q1 2027, compared with $113,784 in the year-ago quarter; YoY change 95%.
- Diluted EPS: $0.02 for Q1 2027, compared with $0.01 in the year-ago quarter.
Business Highlights
- Revenue growth of about 24% was driven by higher distribution volumes and an increased focus on U.S. commercialization.
- Channel shift toward U.S. sales accelerated after the Outflo launch, with domestic sales up 87%.
- Brand momentum from Outflo and Trachealator followed U.S. 510(k) clearances, initiating U.S. market presence and sales.
- Operational milestones include FDA 510(k) clearance for Outflo on March 11, 2025, maintained CE/FDA clearances for key products, and inventory stocking to support distribution.
- Investments in selling and distributor support increased to accelerate market penetration and training.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.